Litcius/Paper detail

FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway

Dong Ma, Pengpeng Liu, Junjun Wen, Yang Gu, Zhangshuo Yang, Jianwei Lan, Haining Fan, Zhisu Liu, Deliang Guo

2022International Journal of Biological Sciences32 citationsDOIOpen Access PDF

Abstract

Hepatocellular carcinoma (HCC) is the third-leading cause of cancer deaths globally. Although considerable progress has been made in the treatment, clinical outcomes of HCC patients are still poor. Therefore, it is necessary to find novel prognostic factors upon which prevention and treatment strategies can be formulated. Ficolin-3 (FCN3) protein is a member of the human ficolin family. It activates complement through pathways associated with mannose-binding lectin-associated serine proteases. Herein, we identified that FCN3 was downregulated in HCC tissues and decreased FCN3 expression was closely related to poor prognosis. Overexpression of FCN3 induced apoptosis and inhibited cell proliferation via the p53 signaling pathway. Mechanistically, FCN3 modulated the nuclear translocation of eukaryotic initiation factor 6 (EIF6) by binding ribosome maturation factor (SBDS), which induced ribosomal stress and activation of the p53 pathway. In addition, Y-Box Binding Protein 1 (YBX1) involved in the transcription and translation level regulation of FCN3 to SBDS. Besides, a negative feedback loop in the downstream of FCN3 involving p53, YBX1 and SBDS was identified.

Topics & Concepts

Cancer researchTranscription factorInitiation factorHepatocellular carcinomaSignal transductionBiologyMdm2Translation (biology)ApoptosisChemistryCell biologyBiochemistryMessenger RNAGeneComplement system in diseasesHistone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors
FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway | Litcius